Nationality Canada Known for HIV/AIDS Role Epidemiologist | Name Martin Schechter Fields Epidemiology | |
Institutions University of British Columbia Alma mater University of British Columbia
Polytechnic Institute of New York
York University
McMaster University
University of Toronto Notable awards Order of British Columbia (1994)
National Health Scientist Award in AIDS
Science Council of British Columbia Gold Medal (2002)
Fellow of the Royal Society of Canada (2004) | ||
Naomi martin schechter hd
Dr. Martin T. Schechter (born December 16, 1951) is a Canadian epidemiologist recognized for contributions to HIV research, prevention and treatments and to addiction research. He is a professor and founding director of the School of Population and Public Health in the Faculty of Medicine at the University of British Columbia (UBC). Schechter received his Order of British Columbia in 1994 alongside BC's first Nobel Prize laureate Michael Smith. He now serves as Chief Scientific Officer of the Michael Smith Foundation for Health Research.
Contents
- Naomi martin schechter hd
- Education
- Contributions to health research
- Heroin trials
- Recognition
- References
Education
Schechter completed his BA in Mathematics at York University (1973), his MA in Mathematics at UBC (1975), his PhD in Mathematics at the Polytechnic Institute of New York (1977), his MD in Medicine at McMaster University (1981) and his MSc in Epidemiology at the University of Toronto (1983).
Contributions to health research
Schechter combines interests in clinical epidemiology and health services research with HIV/AIDS and urban health research including opioid addiction research. He is the author of more than 350 peer-reviewed publications and 530 abstracts and scholarly presentations.
When Schechter first began his work on AIDS research in 1983, there were no reported cases yet in British Columbia and embracing the necessity of an appropriate and humane response to HIV infection was not a popular activity at that time. Airing public service announcements about condoms in movie theatres caused a public and private debate between Schechter and then-Premier of British Columbia Bill Vander Zalm. Had HIV not been such an emerging health crisis, Schechter likely would have continued in the field of breast cancer.
In 1989, he helped organize the Fifth International Conference on AIDS in Montreal as a member of its Steering Committee. In 1990, he was invited by the World Health Organization to participate on its 10-member Steering Committee on Epidemiology, Forecasting and Surveillance that was monitoring the scale of the AIDS epidemic and advising on prevention programs in the early period of the epidemic.
Schechter co-founded the Canadian HIV Trials Network in 1990 with John Ruedy and Julio Montaner. Under Schechter's leadership as National Director from 1992-2014, the Network grew to become a nationwide collaboration of researchers, people living with HIV/AIDS and facilities to investigate treatments, preventions and vaccines for HIV/AIDS.
In 1992, he co-founded and was a director of the British Columbia Centre for Excellence in HIV/AIDS. He was also founding President of the Canadian Association for HIV Research in 1991.
In 1996, Schechter co-chaired the XI International AIDS Conference in Vancouver which attracted 15,000 delegates from around the world. It was at this global conference that the benefits of triple-therapy HAART were first fully revealed.
In 2004, he co-founded the Canadian Academy of Health Sciences, serving as its first President-Elect from 2004-2007 and second President from 2007-2009.
Heroin trials
Schechter was the principal investigator and co-authored a study published in the New England Journal of Medicine about the controversial North American Opiate Medication Initiative (NAOMI). The 2005-2008 study compared the use of diacetylmorphine (heroin) and methadone in street addicts. In the NAOMI study, researchers selected 250 subjects in Vancouver and Montreal with at least five years of heroin addiction and who had twice previously not benefited from addiction treatment including methadone maintenance. Providing injections of medically prescribed heroin in a clinic setting was projected to save about $40,000 per person in lifetime societal costs compared to methadone.The study found those receiving the effective element of heroin were 62 per cent more likely to remain in addiction treatment and 40 per cent less likely to take street drugs and commit crimes to support their habit than those given methadone.
Schechter is involved in the follow-up to NAOMI, the Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) funded by Canadian Institutes of Health Research. In 2013, Federal Health Minister Rona Ambrose controversially cancelled an approval from Health Canada regarding compassionate use of heroin for some research subjects after they completed the trial. Schechter questioned the value placed on research evidence by the federal government. The BMJ requested and published his commentary Drug users should be able to get heroin from the health system in April 2015.